10x Genomics CEO Serge Saxonov Sells Shares in Open-Market Transactions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 01 2026
0mins
Source: Fool
- Transaction Overview: 10x Genomics CEO Serge Saxonov sold 28,893 shares of common stock in multiple open-market transactions between May 22 and May 26, 2026, with an aggregate transaction value of approximately $709,000, indicating his active engagement in the market.
- Historical Comparison: This sale marks Saxonov's largest single open-market transaction in the past two years, exceeding his previous maximum sale of 16,152 shares, suggesting a significant increase in his selling scale that could impact future sale capacity.
- Ownership Changes: Following the sale, Saxonov's direct ownership decreased to 1,138,380 shares, while his total position, including indirect holdings through family trusts, remains at 1,423,301 shares, indicating he still retains substantial control over the company.
- Investor Confidence Maintained: Despite a 3% year-over-year decline in first-quarter revenue to $150.8 million, the company managed to reduce its net loss to $13.5 million, showcasing resilience in the market and maintaining investor optimism regarding its future growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TXG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TXG
Wall Street analysts forecast TXG stock price to fall
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 31.040
Low
9.00
Averages
13.00
High
18.00
Current: 31.040
Low
9.00
Averages
13.00
High
18.00
About TXG
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
10x Genomics CEO Serge Saxonov Sells Shares in Open-Market Transactions
- Transaction Overview: 10x Genomics CEO Serge Saxonov sold 28,893 shares of common stock in multiple open-market transactions between May 22 and May 26, 2026, with an aggregate transaction value of approximately $709,000, indicating his active engagement in the market.
- Historical Comparison: This sale marks Saxonov's largest single open-market transaction in the past two years, exceeding his previous maximum sale of 16,152 shares, suggesting a significant increase in his selling scale that could impact future sale capacity.
- Ownership Changes: Following the sale, Saxonov's direct ownership decreased to 1,138,380 shares, while his total position, including indirect holdings through family trusts, remains at 1,423,301 shares, indicating he still retains substantial control over the company.
- Investor Confidence Maintained: Despite a 3% year-over-year decline in first-quarter revenue to $150.8 million, the company managed to reduce its net loss to $13.5 million, showcasing resilience in the market and maintaining investor optimism regarding its future growth prospects.
See More
10x Genomics CEO Sells $709,000 in Shares Amid Strong Stock Performance
- Executive Share Sale: 10x Genomics CEO Serge Saxonov sold 28,893 shares of common stock between May 22 and May 26, 2026, for approximately $709,000, demonstrating executive liquidity management amid stock performance.
- Stable Holdings: Despite the sale, Saxonov retains over 1.4 million shares in direct and indirect holdings, indicating his confidence in the company's future and commitment to ongoing investment.
- Compliance in Trading: The share sale was executed under a Rule 10b5-1 trading plan established in November 2025, aimed at avoiding insider trading allegations, showcasing the company's governance transparency and compliance.
- Improved Financial Performance: Although 10x Genomics reported a 3% year-over-year revenue decline to $150.8 million in Q1, effective cost management reduced net losses to $13.5 million, reflecting the company's ability to maintain profitability in challenging conditions.
See More
Torex Gold Restarts Drilling at Los Reyes Project
- Drilling Program Restart: Torex Gold has restarted drilling at the Los Reyes project in Sinaloa, Mexico, planning to drill approximately 20,000 meters in 2026, aimed at de-risking and upgrading mineral resources while supporting future economic studies.
- Investment Scale: The company expects to invest about $18 million in the Los Reyes project in 2026, with the majority allocated to exploration and drilling, and the remainder earmarked for completing the preliminary economic assessment (PEA) and commencing feasibility studies, reflecting strong confidence in the project.
- Community Engagement: Torex has established long-term agreements with local communities and engaged with key stakeholders in state and federal governments to secure permits for the 2026 drilling program, demonstrating a commitment to social responsibility and compliance in project advancement.
- Strategic Objectives: Torex's strategic goals include optimizing production and costs at Morelos, driving resource growth, and becoming an industry leader in responsible mining, with the success of the Los Reyes project expected to create significant value for shareholders.
See More
10x Genomics Q1 Results Beat Expectations but Shares Drop
- Earnings Beat: 10x Genomics reported Q1 revenue of $150.8 million, a 2.6% year-over-year decline that, while exceeding Wall Street expectations, failed to boost investor sentiment, highlighting concerns about future growth prospects.
- Stock Volatility: The company's shares fell 5.3% in the afternoon session, closing at $21.61, down 3.6% from the previous close, reflecting investor caution regarding the company's growth potential in the near term.
- Market Reaction: With over 54 moves greater than 5% in the past year, today's decline indicates that the market considers this news significant, yet it does not fundamentally alter perceptions of the business.
- Long-term Investment Returns: Despite a 29.9% increase year-to-date, the stock is still trading 17.2% below its 52-week high, indicating poor returns for long-term investors, as those who invested $1,000 five years ago would now see only $160.12.
See More
Quantedge Capital Increases Stake in 10x Genomics
- Stake Increase: On May 12, 2026, Quantedge Capital disclosed in an SEC filing that it purchased 212,600 shares of 10x Genomics, valued at approximately $4.25 million, indicating confidence in the company's growth prospects.
- Value Growth: The recent stake increase resulted in a $5.52 million rise in the value of 10x Genomics' position at quarter-end, reflecting both the addition of shares and market price changes, thereby boosting investor confidence in its market performance.
- Financial Performance: Although 10x Genomics reported a 3% year-over-year decline in first-quarter revenue to $150.8 million, excluding one-time litigation revenue, actual sales grew by 9%, demonstrating strong market demand for its products.
- Product Innovation: The recent launch of the Atera platform, described as the most significant product introduction in the company's history, aims to advance spatial whole-transcriptome analysis, potentially laying the groundwork for AI-driven biological modeling and precision medicine.
See More
Torex Gold Resources Sees Major Earnings Upgrade
- Revenue Forecast Upgrade: The analyst raised Torex Gold Resources' 2026 revenue forecast from $2.0 billion to $2.3 billion, anticipating a significant 35% annual growth rate, which is a stark improvement over the historical 9.7% growth rate, indicating a strong enhancement in business fundamentals and future growth potential.
- Earnings Per Share Surge: Expected earnings per share are projected to rise from $6.48 to $7.86, marking a 28% increase, which not only reflects improved profitability but also has the potential to attract more investor interest, thereby driving the stock price higher.
- Positive Market Sentiment: Over the past week, Torex Gold's stock has surged 17% to CA$65.29, showcasing investor confidence in the company's growth prospects, and the analyst's upgrade may further propel the stock price, enhancing market recognition.
- Competitive Industry Position: Torex Gold's projected growth rate significantly outpaces the 17% annual growth forecast for other companies in the same industry, highlighting its competitive advantage; the analyst's optimistic outlook may draw more investor attention, bolstering its market position.
See More
10x Genomics CEO Serge Saxonov Sells Shares in Open-Market Transactions
- Transaction Overview: 10x Genomics CEO Serge Saxonov sold 28,893 shares of common stock in multiple open-market transactions between May 22 and May 26, 2026, with an aggregate transaction value of approximately $709,000, indicating his active engagement in the market.
- Historical Comparison: This sale marks Saxonov's largest single open-market transaction in the past two years, exceeding his previous maximum sale of 16,152 shares, suggesting a significant increase in his selling scale that could impact future sale capacity.
- Ownership Changes: Following the sale, Saxonov's direct ownership decreased to 1,138,380 shares, while his total position, including indirect holdings through family trusts, remains at 1,423,301 shares, indicating he still retains substantial control over the company.
- Investor Confidence Maintained: Despite a 3% year-over-year decline in first-quarter revenue to $150.8 million, the company managed to reduce its net loss to $13.5 million, showcasing resilience in the market and maintaining investor optimism regarding its future growth prospects.
See More
10x Genomics CEO Sells $709,000 in Shares Amid Strong Stock Performance
- Executive Share Sale: 10x Genomics CEO Serge Saxonov sold 28,893 shares of common stock between May 22 and May 26, 2026, for approximately $709,000, demonstrating executive liquidity management amid stock performance.
- Stable Holdings: Despite the sale, Saxonov retains over 1.4 million shares in direct and indirect holdings, indicating his confidence in the company's future and commitment to ongoing investment.
- Compliance in Trading: The share sale was executed under a Rule 10b5-1 trading plan established in November 2025, aimed at avoiding insider trading allegations, showcasing the company's governance transparency and compliance.
- Improved Financial Performance: Although 10x Genomics reported a 3% year-over-year revenue decline to $150.8 million in Q1, effective cost management reduced net losses to $13.5 million, reflecting the company's ability to maintain profitability in challenging conditions.
See More
Torex Gold Restarts Drilling at Los Reyes Project
- Drilling Program Restart: Torex Gold has restarted drilling at the Los Reyes project in Sinaloa, Mexico, planning to drill approximately 20,000 meters in 2026, aimed at de-risking and upgrading mineral resources while supporting future economic studies.
- Investment Scale: The company expects to invest about $18 million in the Los Reyes project in 2026, with the majority allocated to exploration and drilling, and the remainder earmarked for completing the preliminary economic assessment (PEA) and commencing feasibility studies, reflecting strong confidence in the project.
- Community Engagement: Torex has established long-term agreements with local communities and engaged with key stakeholders in state and federal governments to secure permits for the 2026 drilling program, demonstrating a commitment to social responsibility and compliance in project advancement.
- Strategic Objectives: Torex's strategic goals include optimizing production and costs at Morelos, driving resource growth, and becoming an industry leader in responsible mining, with the success of the Los Reyes project expected to create significant value for shareholders.
See More
10x Genomics Q1 Results Beat Expectations but Shares Drop
- Earnings Beat: 10x Genomics reported Q1 revenue of $150.8 million, a 2.6% year-over-year decline that, while exceeding Wall Street expectations, failed to boost investor sentiment, highlighting concerns about future growth prospects.
- Stock Volatility: The company's shares fell 5.3% in the afternoon session, closing at $21.61, down 3.6% from the previous close, reflecting investor caution regarding the company's growth potential in the near term.
- Market Reaction: With over 54 moves greater than 5% in the past year, today's decline indicates that the market considers this news significant, yet it does not fundamentally alter perceptions of the business.
- Long-term Investment Returns: Despite a 29.9% increase year-to-date, the stock is still trading 17.2% below its 52-week high, indicating poor returns for long-term investors, as those who invested $1,000 five years ago would now see only $160.12.
See More
Quantedge Capital Increases Stake in 10x Genomics
- Stake Increase: On May 12, 2026, Quantedge Capital disclosed in an SEC filing that it purchased 212,600 shares of 10x Genomics, valued at approximately $4.25 million, indicating confidence in the company's growth prospects.
- Value Growth: The recent stake increase resulted in a $5.52 million rise in the value of 10x Genomics' position at quarter-end, reflecting both the addition of shares and market price changes, thereby boosting investor confidence in its market performance.
- Financial Performance: Although 10x Genomics reported a 3% year-over-year decline in first-quarter revenue to $150.8 million, excluding one-time litigation revenue, actual sales grew by 9%, demonstrating strong market demand for its products.
- Product Innovation: The recent launch of the Atera platform, described as the most significant product introduction in the company's history, aims to advance spatial whole-transcriptome analysis, potentially laying the groundwork for AI-driven biological modeling and precision medicine.
See More
Torex Gold Resources Sees Major Earnings Upgrade
- Revenue Forecast Upgrade: The analyst raised Torex Gold Resources' 2026 revenue forecast from $2.0 billion to $2.3 billion, anticipating a significant 35% annual growth rate, which is a stark improvement over the historical 9.7% growth rate, indicating a strong enhancement in business fundamentals and future growth potential.
- Earnings Per Share Surge: Expected earnings per share are projected to rise from $6.48 to $7.86, marking a 28% increase, which not only reflects improved profitability but also has the potential to attract more investor interest, thereby driving the stock price higher.
- Positive Market Sentiment: Over the past week, Torex Gold's stock has surged 17% to CA$65.29, showcasing investor confidence in the company's growth prospects, and the analyst's upgrade may further propel the stock price, enhancing market recognition.
- Competitive Industry Position: Torex Gold's projected growth rate significantly outpaces the 17% annual growth forecast for other companies in the same industry, highlighting its competitive advantage; the analyst's optimistic outlook may draw more investor attention, bolstering its market position.
See More
